Open Access. Powered by Scholars. Published by Universities.®
Antitrust and Trade Regulation Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Competition (2)
- Federal agencies (2)
- Antitrust (1)
- Antitrust Division (1)
- Corporations (1)
-
- Criminal Division (1)
- Criminal liability (1)
- Criminal prosecution of corporations (1)
- Deferred prosecution (1)
- Deterrent value (1)
- Drug Price Competition and Patent Term Restoration Act (1)
- Drug approvals (1)
- Drugs (1)
- Enforcement (1)
- Expressive theory (1)
- Expressive value (1)
- Federal Trade Commission (1)
- Food and Drug Administration (1)
- Global financial crisis (1)
- Incentives (1)
- Intel (1)
- Justice Department (1)
- Markets (1)
- Moral content (1)
- Non-prosecution agreements (1)
- Norm-setting (1)
- Orphan Drug Act (1)
- Patent law (1)
- Pharmaceuticals (1)
- Punishment (1)
Articles 1 - 3 of 3
Full-Text Articles in Antitrust and Trade Regulation
The Pendulum Swings: Reconsidering Corporate Criminal Prosecution, David M. Uhlmann
The Pendulum Swings: Reconsidering Corporate Criminal Prosecution, David M. Uhlmann
Articles
Corporate crime continues to occur at an alarming rate, yet disagreement persists among scholars and practitioners about the role of corporate criminal prosecution. Some argue that corporations should face criminal prosecution for their misconduct, while others would reserve criminal prosecution for individual corporate officials. Perhaps as a result of this conflict, there has been a dramatic increase over the last decade in the use of deferred prosecution and non-prosecution agreements for some corporate crimes, even as the government continues to bring criminal charges for other corporate crimes. To move beyond our erratic approach to corporate crime, we need a better …
Reflections On Section 5 Of The Ftc Act And The Ftc's Case Against Intel, Daniel A. Crane
Reflections On Section 5 Of The Ftc Act And The Ftc's Case Against Intel, Daniel A. Crane
Articles
The Federal Trade Commission’s (“FTC’s”) unprecedented enforcement action against Intel raises profound issues concerning the scope of the FTC’s powers to give a construction to Section 5 of the FTC Act that goes beyond the substantive reach of the Sherman Act. While I have urged the FTC to assert such independence from the Sherman Act, this is the wrong case to make a break. Indeed, if anything, Intel poses a risk of seriously setting back the development of an independent Section 5 power by provoking a hostile appellate court to rebuke the FTC’s effort and cabin the FTC’s powers in …
The Problem Of New Uses, Rebecca S. Eisenberg
The Problem Of New Uses, Rebecca S. Eisenberg
Articles
Discovering new uses for drugs that are already on the market seems like it ought to be the low-lying fruit of biopharmaceutical research and development (R&D). Firms have already made significant investments in developing these drugs and bringing them to market, including testing them in clinical trials, shepherding them through the FDA regulatory approval process, building production facilities, and training sales staff to market them to physicians. By this point, the drugs have begun to enjoy goodwill among patients and physicians and casual observations in the course of clinical experience may point to potential new uses. One might expect that …